Skip to Content

Bosulif Approval History

FDA Approved: Yes (First approved September 4, 2012)
Brand name: Bosulif
Generic name: bosutinib
Dosage form: Tablets
Company: Pfizer Inc.
Treatment for: Chronic Myelogenous Leukemia

Bosulif (bosutinib) is a kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML).

Development History and FDA Approval Process for Bosulif

DateArticle
Dec 19, 2017Approval FDA Approves Pfizer’s Bosulif (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)
Sep  4, 2012Approval FDA Approves Bosulif for Chronic Myelogenous Leukemia
Jan 30, 2012Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide